Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | CMO & Head of Late-Stage Dev. | July 16, 2026 | July 20, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 21, 2022 | June 23, 2022 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,118 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Sale · Disposed 1,877 · Balance 21,118 |
| Common StockSEC Table I · non-derivative | Direct | 30,916 |
Reported balance
After 2026-07-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 9,798 · Balance 30,916 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-07-16 | Direct | 24,496 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Grant · Acquired 24,496 · Balance 24,496 F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.65 · Expires 2036-07-15 | Direct | 42,298 |
Reported balance
After 2026-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-16 · Grant · Acquired 42,298 · Balance 42,298 F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Kura Oncology, Inc.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.84 · Expires 2032-06-20 | Direct | 23,000 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 23,000 · Balance 23,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 54,000 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 54,000 · Balance 54,000 F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theseus Pharmaceuticals, Inc.
Report date February 14, 2024 · Filed February 14, 2024
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2023 Filed Jun 13, 2023 17:30 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantRestricted Stock Unit · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001745020-23-000040 · wk-form4_1686691799.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001 per share, when vested. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. Read SEC document |
| June 13, 2023 Filed Jun 13, 2023 17:30 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001745020-23-000040 · wk-form4_1686691799.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-12 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 27,096 | $0.00 Strike: $83.20 | $0.00 |
DisclosureSEC source: 0001209191-23-004568 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,096 Underlying: Common Stock · 27,096 shares Expires 2033-01-19 F3 · derivative.exercise_date: Beginning January 20, 2023, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2023 and the remainder vesting monthly over three years. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004568 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,001 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on January 20, 2023. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 92,490 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. The aggregate amount also includes the additional Performance Stock Units earned on January 20, 2023. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:00 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 28,399 | $79.78 | $2,265,672.22 |
DisclosureSEC source: 0001209191-23-002318 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,021 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 87,510 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 07:18 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001104659-22-109824 · tm2228422-2_4seq1.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-10-17 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a three-year period with 1/36th of the options vesting on November 17, 2022 and 1/36th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer on each such vesting date. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 20:11 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 3,856 | $79.25 | $305,588.00 |
DisclosureSEC source: 0001209191-22-041082 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,420 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2022 RSU Grant, this includes an aggregate of 68,569 shares of common stock issuable pursuant to previously RSUs and earned performance shares that have not vested. Read SEC document |
| July 02, 2022 Filed Jul 6, 2022 20:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 25,665 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001209191-22-041082 · doc4.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,665 Underlying: Common Stock · 25,665 shares Expires 2032-07-01 F4 · derivative.exercise_date: Beginning July 2, 2022, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2022 Filed Jul 6, 2022 20:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 18,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041082 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,276 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 11,488 | $75.63 | $868,837.44 |
DisclosureSEC source: 0001209191-22-039904 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,335 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 76,955 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:47 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001209191-22-038922 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:24 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $74.78 | $0.00 |
DisclosureSEC source: 0001209191-22-004429 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2032-01-18 F1 · derivative.exercise_date: Beginning January 19, 2022, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2022 and the remainder vesting monthly over three years. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 21:21 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 28,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001670 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,823 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on December 31, 2025, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 101,955 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:27 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066430 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,897 F2 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2021 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in February 2021 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F3 · balance_after: Including the Performance Stock Units earned on November 19, 2021, this includes an aggregate of 73,029 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:27 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 379 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066430 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,542 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 19, 2021. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 21:43 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 402 | $83.34 | $33,502.68 |
DisclosureSEC source: 0001209191-21-045888 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,163 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2021 Restricted Stock Unit Grant, this includes an aggregate of 70,295 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:43 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 15,054 | $0.00 Strike: $83.58 | $0.00 |
DisclosureSEC source: 0001209191-21-045888 · doc4.xml · derivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock · 15,054 shares Expires 2031-07-01 F4 · derivative.exercise_date: Beginning July 2, 2021, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:43 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,953 | $83.58 | $246,811.74 |
DisclosureSEC source: 0001209191-21-045888 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,565 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 21:43 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045888 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,518 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:14 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 22,079 | $85.61 | $1,890,183.19 |
DisclosureSEC source: 0001209191-21-043978 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,665 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 69,744 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042785 · doc4.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,795 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-21-005718 · doc4.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,539 Underlying: Common Stock · 3,795 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:09 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,795 | $100.00 | $379,500.00 |
DisclosureSEC source: 0001209191-21-005718 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,744 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · balance_after: This includes an aggregate of 119,744 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 22:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 3,795 | $68.62 | $260,412.90 |
DisclosureSEC source: 0001209191-21-005718 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,743 | $0.00 Strike: $90.56 | $0.00 |
DisclosureSEC source: 0001209191-21-004378 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,743 Underlying: Common Stock · 12,743 shares Expires 2031-01-14 F3 · derivative.exercise_date: Beginning January 15, 2021, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2021 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 22:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 23,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004378 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,744 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 100% on the fourth anniversary of the grant date of January 15, 2021, subject to Steven Stein's continued service with the Issuer through the applicable vesting date. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the January 15, 2021 Restricted Stock Unit Grant, this includes an aggregate of 119,744 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:55 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059152 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,700 F1 · shares: Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. F2 · balance_after: Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 96,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:20 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 766 | $103.83 | $79,533.78 |
DisclosureSEC source: 0001209191-20-042829 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,468 F2 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F3 · balance_after: This includes an aggregate of 95,468 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 623 | $104.25 | $64,947.75 |
DisclosureSEC source: 0001209191-20-042829 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,234 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 610 | $108.56 | $66,221.60 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,857 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F5 · balance_after: This includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,495 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · derivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,495 shares Expires 2015-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,381 | $0.00 Strike: $88.68 | $0.00 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,381 shares Expires 2015-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning March 2, 2015, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,283 | $107.99 | $354,531.17 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,467 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $107.04 - $108.79. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 7,495 | $110.04 | $824,749.80 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $110.00 - $110.07. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 7,495 | $88.68 | $664,656.60 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,381 | $110.04 | $372,045.24 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $110.00 - $110.07. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:27 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 3,381 | $88.68 | $299,827.08 |
DisclosureSEC source: 0001209191-20-041784 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,437 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · derivative · entry 17 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,334 Underlying: Common Stock · 10,437 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,437 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · derivative · entry 16 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,335 Underlying: Common Stock · 10,437 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,132 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · derivative · entry 15 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194 Underlying: Common Stock · 12,132 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 596 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · derivative · entry 14 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 596 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,437 | $107.31 | $1,119,994.47 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 12 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F7 · price: Represents weighted average sale price. Actual sale prices ranged from $105.65 - $108.48 F8 · balance_after: Including the July 2, 2020 Restricted Stock Unit Grant, this includes an aggregate of 96,857 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 10,437 | $68.62 | $716,186.94 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 11 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,437 | $107.31 | $1,119,994.47 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 10 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F7 · price: Represents weighted average sale price. Actual sale prices ranged from $105.65 - $108.48 Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 10,437 | $72.27 | $754,281.99 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 9 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 12,132 | $107.31 | $1,301,884.92 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 8 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $105.64 - $108.24. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 12,132 | $83.83 | $1,017,025.56 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 596 | $107.31 | $63,956.76 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $105.64 - $108.24. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 596 | $83.83 | $49,962.68 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2020 Filed Jul 7, 2020 23:25 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,522 | $106.40 | $268,340.80 |
DisclosureSEC source: 0001209191-20-041566 · doc4.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,750 F3 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F4 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $105.52 - $107.29. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.